Vir Biotechnology (VIR) Common Equity (2018 - 2026)
Vir Biotechnology (VIR) posted Common Equity of $812.8 million for Q1 2026, up 6.21% sequentially from $765.3 million in Q4 2025, and down 22.14% YoY from $1.0 billion in Q1 2025.
Vir Biotechnology (VIR) Common Equity (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Common Equity for 9 years, with the latest figure at $812.8 million in Q1 2026.
- Quarterly Common Equity fell 22.14% year-over-year to $812.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $812.8 million (down 22.14% YoY) and the FY2025 annual result came in at $765.3 million, down 33.48% from the prior year.
- Common Equity grew to $812.8 million in Q1 2026 per VIR's latest filing, from $765.3 million in the prior quarter.
- Over five years, Common Equity peaked at $2.1 billion in Q3 2022 and troughed at $765.3 million in Q4 2025.
- A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity jumped 207.4% in 2022, then tumbled 35.84% in 2025.
- Over 5 years, Common Equity stood at $2.1 billion in 2022, then dropped by 23.47% to $1.6 billion in 2023, then slipped by 27.66% to $1.2 billion in 2024, then plunged by 33.48% to $765.3 million in 2025, then climbed by 6.21% to $812.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $812.8 million, $765.3 million, and $796.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 982.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 982.49 Mn |
| Mar 31, 2026 | 812.77 Mn |
| Dec 31, 2025 | 765.28 Mn |
| Sep 30, 2025 | 796.10 Mn |
| Jun 30, 2025 | 947.47 Mn |
| Mar 31, 2025 | 1.04 Bn |
| Dec 31, 2024 | 1.15 Bn |
| Sep 30, 2024 | 1.24 Bn |
| Jun 30, 2024 | 1.43 Bn |
| Mar 31, 2024 | 1.55 Bn |
| Dec 31, 2023 | 1.59 Bn |
| Sep 30, 2023 | 1.68 Bn |
| Jun 30, 2023 | 1.81 Bn |
| Mar 31, 2023 | 1.97 Bn |
| Dec 31, 2022 | 2.08 Bn |
| Sep 30, 2022 | 2.15 Bn |
| Jun 30, 2022 | 1.95 Bn |
| Mar 31, 2022 | 2.00 Bn |
| Dec 31, 2021 | 1.43 Bn |
| Sep 30, 2021 | 876.27 Mn |